Hälsa & medicin
7.5
🇸🇪
New drug shows promise in treatment of rare autoimmune muscle disease
A Phase 3 trial published in the New England Journal of Medicine has tested brepocitinib for dermatomyositis, a rare autoimmune condition that attacks skin and muscles. The result could expand treatment options for patients with this debilitating disease and signal a new therapeutic pathway for related autoimmune disorders.
Originaltitel: A Phase 3 Trial of Brepocitinib in Dermatomyositis